This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Tonnessen, B. H. Articles by Money, S. R. Search for Related Content PubMed Articles by Tonnessen, B. H. Articles by Money, S. R. Social Bookmarking                         What's this?

Low-Molecular-Weight Heparin Versus Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients With Cancer

Ochsner Clinic Foundation, 1516 Jefferson Highway, New Orleans, LA 70123

Samuel R. Money, MD, MBA

Ochsner Clinic Foundation, 1516 Jefferson Highway, New Orleans, LA 70123; smoney{at}ochsner.org

Patients with cancer have a substantial risk of recurrent thromboembolism and hemorrhage when they received standard oral anticoagulant therapy for the treatment and prevention of acute venous thromboembolism. The authors performed a six-month, multicenter, randomized open-label clinical trial to investigate whether low-molecular-weight heparin is a safe and effective therapy in preventing recurrent thromboembolism in this group of patients. Cancer patients with deep vein thrombosis, pulmonary embolism, or both, were randomly assigned to receive (1) low-molecular-weight heparin subcutaneously and a coumarin derivative for 6 months (336 patients), or (2) the low-molecular-weight heparin alone for 6 months (336 patients). In the oral anticoagulation group, 53 of 336 patients had recurrent venous thromboembolism, compared with 27 of 336 patients in the low-molecular-weight heparin group. No significant difference was detected between the groups in the rate of bleeding. The low-molecular-weight heparin group had a lower mortality rate (39%) than the oral anticoagulation group (41%). The authors concluded that lowmolecular-weight heparin was more effective than an oral anticoagulant in reducing the risk of recurrent thromboembolism and did not increase the risk of bleeding.

Key Words: venous thromboembolism • low-molecular-weight heparin • warfarin resistance • recurrence

Perspectives in Vascular Surgery and Endovascular Therapy, Vol. 16, No. 2, 144-146 (2004)
DOI: 10.1177/153100350401600217


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?